Hepatitis C virus treatment and survival in patients with hepatitis C and human immunodeficiency virus co-infection and baseline anaemia

Journal of Viral Hepatitis

Volumn 20, Issue 7, 2013, Pages 463-469

  Erqou, S ^a,b   Mohanty, A ^a   McGinnis, K A ^b   Vanasse, G ^c   Freiberg, M S ^a,b   Sherman, K E ^d   Butt, A A ^a,b,e  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Veterans Administration   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

Author keywords

anemia; HCV; HIV; survival; treatment

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL;

ANEMIA; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84878573538     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12107     Document Type: Article

References (28)

1. El-Serag HB,. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002; 36 (5 Suppl 1): S74-S83.
2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ,. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144 (10): 705-714.
3. Rustgi VK,. The epidemiology of hepatitis C infection in the United States. J Gastroenterol 2007; 42 (7): 513-521.
4. Soriano V, Sulkowski M, Bergin C, et al,. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16 (6): 813-828.
5. Laguno M, Murillas J, Blanco JL, et al,. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18 (13): F27-F36.
6. Sulkowski MS, Thomas DL,. Hepatitis C in the HIV-infected person. Ann Intern Med 2003; 138 (3): 197-207.
7. Chung RT, Andersen J, Volberding P, et al,. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351 (5): 451-459.
8. Butt AA, Wang X, Moore CG,. Effect of hepatitis C virus and its treatment on survival. Hepatology 2009; 50 (2): 387-392.
9. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA,. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9 (6): 509-516.
10. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49 (4): 1335-1374.
11. Fried MW,. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36 (5 Suppl 1): S237-S244.
12. Hiramatsu N, Kurosaki M, Sakamoto N, et al,. Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis. J Gastroenterol 2011; 46 (9): 1111-1119.
13. Takaki S, Tsubota A, Hosaka T, et al,. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol 2004; 39 (7): 668-673.
14. Nachnani JS, Rao GA, Bulchandani D, Pandya PK, Alba LM,. Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin. Ann Hematol 2010; 89 (2): 121-125.
15. Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK,. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56 (3): 385-389.
16. Butt AA, McGinnis KA, Skanderson M, Justice AC,. Hepatitis C treatment completion rates in routine clinical care. Liver Int 2010; 30 (2): 240-250.
17. Butt AA, Khan UA, McGinnis KA, Skanderson M, Kent KC,. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. J Viral Hepat 2007; 14 (12): 890-896.
18. Butt AA, Wang X, Fried LF,. HCV infection and the incidence of CKD. Am J Kidney Dis 2011; 57 (3): 396-402.
19. Butt AA, McGinnis K, Rodriguez-Barradas MC, et al,. HIV infection and the risk of diabetes mellitus. AIDS 2009; 23 (10): 1227-1234.
20. Fultz SL, Skanderson M, Mole LA, et al,. Development and verification of a "virtual" cohort using the National VA Health Information System. Med Care 2006; 44 (8 Suppl 2): S25-S30.
21. Robinson BM, Joffe MM, Berns JS, Pisoni RL, Port FK, Feldman HI,. Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int 2005; 68 (5): 2323-2330.
22. Zakai NA, Katz R, Hirsch C, et al,. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. Arch Intern Med 2005; 165 (19): 2214-2220.
23. Groenveld HF, Januzzi JL, Damman K, et al,. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008; 52 (10): 818-827.
24. Sievert W, Dore GJ, McCaughan GW, et al,. Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology 2011; 53 (4): 1109-1117.
25. Sulkowski MS,. Anemia in the treatment of hepatitis C virus infection. Clin Infect Dis 2003; 37 (Suppl 4): S315-S322.
26. Dieterich DT,. Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients. J Infect Dis 2002; 185 (Suppl 2): S128-S137.
27. Sulkowski MS, Shiffman ML, Afdhal NH, et al,. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 2010; 139 (5): 1602-1611.
28. Gonzalez-Casas R, Jones EA, Moreno-Otero R,. Spectrum of anemia associated with chronic liver disease. World J Gastroenterol 2009; 15 (37): 4653-4658.